/
Oncology
Solid Tumor
449
Pipeline Programs↗
430
Active Trials↗
232
Companies Involved↗
Solid Tumor is a highly competitive landscape with 449 programs across 232 companies. The most active players are Roche, AstraZeneca, Incyte. 12 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical118
Phase 1233
Phase 286
Phase 312
Approved
No programs
Analysis
Modality Breakdown
82%
Small molecule
291 of 353 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 353 classified programs, each share of the total. Modality classified for 85% of 449 pipeline programs.
Analysis
Trial Status
657
clinical trials
Recruiting283 · 43%
Completed147 · 22%
Active, not recruiting84 · 13%
Not yet recruiting57 · 9%
Terminated45 · 7%
Unknown status18 · 3%
Other23 · 4%
Clinical Trials
Trial Activity
657 trials
Page 1 of 44
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)